Bioxyne expands its LATAM footprint by securing the first international medicinal cannabis flower supply agreement in Costa Rica, with initial shipments valued over $500,000 planned before June 2026.
- First international medicinal cannabis flower supply to Costa Rica
- Expanded agreement with Remidose LATAM covers three Dr Watson® flower SKUs
- Initial shipment valued above $500,000 scheduled before June 30, 2026
- Builds on existing pastilles supply agreement for Costa Rica and Panama
- Establishes early market foothold for broader LATAM expansion
Strategic First-Mover Entry into Costa Rica's Medicinal Cannabis Market
Bioxyne Limited (ASX:BXN) has taken a significant step in its Latin American expansion by securing the first international supply agreement for medicinal cannabis flower into Costa Rica's newly regulated market. Through its subsidiary Breathe Life Sciences (BLS), Bioxyne will supply three Dr Watson® cannabis flower SKUs to Remidose LATAM, marking a pioneering entry ahead of other international competitors. The initial shipment, expected before 30 June 2026, carries an invoice value exceeding $500,000, signalling strong early demand and confidence in the market's growth potential.
This expanded agreement builds on a December 2025 deal where BLS supplied cannabis pastilles to Costa Rica and Panama, reinforcing a growing partnership with Remidose LATAM. The move cements Bioxyne's first-mover advantage in Costa Rica and sets a foundation for further regional growth leveraging Remidose's established distribution network across LATAM.
Leveraging GMP Manufacturing and Brand Positioning
Bioxyne's supply of GMP-manufactured cannabis flower under the Dr Watson® brand aligns with its broader strategy to scale internationally across regulated markets. Costa Rica’s medicinal cannabis sector remains in its infancy, with evolving regulations and limited competition, presenting an attractive opportunity for early entrants. The company's established export capabilities and regulatory expertise have enabled this early market access, positioning Dr Watson® as a leading brand before other international suppliers complete approval pathways.
CEO Sam Watson emphasised the rapid evolution from initial agreements to expanded supply scope, highlighting the strength of the partnership and on-the-ground demand. This strategic positioning is designed to open doors to other LATAM jurisdictions as regulatory frameworks mature and patient access expands. The agreement also reflects Bioxyne’s ongoing rollout of its Dr Watson® brand across international markets, underpinning its growth trajectory.
Regional Growth Supported by Strong Demand and Distribution
Remidose Managing Director Michael Mayne expressed enthusiasm about delivering the first medicinal cannabis flower shipment into Costa Rica, noting early demand indications that may fully commit initial stock before market arrival. This underscores the latent potential within the LATAM region and the mutual benefits of the Bioxyne-Remidose alliance. The partnership extends beyond Costa Rica, with plans to supply pastilles to Panama, further broadening Bioxyne’s LATAM footprint.
This development complements Bioxyne’s recent performance, including record quarterly revenues and manufacturing deals with global players, reinforcing its position as a pharmaceutical-grade cannabis manufacturer. The company’s ability to secure and expand supply agreements in emerging markets like LATAM reflects its strategic focus on growth regions alongside Europe, as seen in its broader international expansion efforts and partnerships with firms such as Aurora Cannabis. The LATAM push is part of a wider narrative of Bioxyne capitalising on early-stage market opportunities and regulatory openings, as highlighted in its recent record $21.3m quarterly revenue and manufacturing agreement with Aurora Cannabis.
Market Risks and Future Catalysts
While the initial shipment and agreement signal momentum, the sustainability of demand and repeat orders remain contingent on regulatory approvals and evolving market conditions in Costa Rica and the broader LATAM region. The nascent nature of these markets means Bioxyne must navigate regulatory uncertainties and competitive pressures as other international suppliers progress through approval pathways.
Investors should monitor shipment execution, regulatory developments, and competitive dynamics closely to assess how Bioxyne leverages its first-mover advantage. The company’s ability to scale GMP-certified manufacturing and expand its Dr Watson® brand will be critical to capturing long-term growth in LATAM’s medicinal cannabis sector.
Bottom Line?
Bioxyne’s pioneering supply of medicinal cannabis flower to Costa Rica sets a strategic foothold in LATAM, but market evolution and regulatory hurdles will test its staying power.
Questions in the middle?
- Will Bioxyne secure repeat orders amid evolving LATAM regulations?
- How quickly will other international suppliers enter Costa Rica’s medicinal cannabis market?
- What impact will Remidose’s regional distribution network have on Bioxyne’s LATAM expansion?